Evidence map›Paper›PMID 36179954›Full record

ArticlePharmacological research2022

Negative allosteric modulation of CB

Vishakh Iyer, Claudia Rangel-Barajas, Taylor J Woodward, Abhijit Kulkarni, Lucas Cantwell, Jonathon D Crystal, Ken Mackie, George V Rebec, Ganesh A Thakur, Andrea G Hohmann

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Impact of ΔThe Journal of pharmacology and experimental therapeutics · 2026
    Article
  2. Article
  3. Article
  4. Efficacy of GABA aminotransferase inactivator OV329 in models of neuropathic and inflammatory pain without tolerance or addiction.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Negative allosteric modulation of CBNeuropharmacology · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Vishakh IyerProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Claudia Rangel-BarajasProgram in Neuroscience, Indiana University, Bloomington, IN, USA.
Taylor J WoodwardProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Abhijit KulkarniDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Lucas CantwellDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Jonathon D CrystalProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Ken MackieProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.
George V RebecProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.
Ganesh A ThakurDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Andrea G HohmannProgram in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA. Electronic address: hohmanna@indiana.edu.
Indiana University Bloomington · USNortheastern University · US

Funding

Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0M
INTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITYT32DA024628 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Andrea Grace Hohmann, Kenneth Mackie · 2008 to 2026
$3.1M
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and DependenceR01DA047858 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2019 to 2023
$2.6M
A Novel Pharmacotherapy for GlaucomaR01EY024717 · NEI · NORTHEASTERN UNIVERSITY · PI THAKUR, GANESH A · 2014 to 2018
$2.2M
Role of CB2 in Analgesic MechanismsR01DA041229 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, MACKIE, KENNETH · 2016 to 2020
$1.8M
A Novel Mechanism for Decreasing Opioid RewardR21DA042584 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI HOHMANN, ANDREA GRACE, REBEC, GEORGE VINCENT · 2016 to 2017
$392k
Allosteric Modulators of CB1 Cannabinoid ReceptorR03DA027113 · NIDA · NORTHEASTERN UNIVERSITY · PI THAKUR, GANESH A · 2009 to 2010
$390k
NEI NIH HHS R01 EY024717NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA041229NIDA NIH HHS R01 DA047858NIDA NIH HHS R03 DA027113NIDA NIH HHS R21 DA042584NIDA NIH HHS T32 DA024628
6 · The paper itself

Abstract

Blockade of cannabinoid type 1 (CB

Indexed as

Analgesics, OpioidDopamineAnimalsMaleMiceMice, KnockoutMorphineReceptor, Cannabinoid, CB1Receptors, CannabinoidRewardAnalgesics, OpioidDopamineMorphineReceptor, Cannabinoid, CB1Receptors, CannabinoidAllosteric modulatorCB(1)EndocannabinoidMorphineOpioidReward

Identifiers

PMID36179954
PMCPMC9948526
OpenAlexW4297537798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.